Ingevity Corp (NGVT) director reports 396-share DSU-based stock acquisition
Rhea-AI Filing Summary
Ingevity Corp director reports routine stock-based compensation. Director Francis David Segal acquired 396 shares of Ingevity common stock on 01/02/2026 at a price of $60.09 per share. Following this transaction, he beneficially owns 6,051 shares of Ingevity common stock in direct ownership.
The reported shares represent vested deferred stock units that were granted under Ingevity’s director compensation programs, where the director elected to receive deferred stock units instead of cash quarterly director fees. These deferred stock units will convert into an equal number of Ingevity common shares when his service on the board ends, in line with the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 396 | $60.09 | $24K |
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Ingevity Corp (NGVT) disclose in this filing?
Ingevity Corp disclosed that director Francis David Segal acquired 396 shares of its common stock on 01/02/2026, reported as vested deferred stock units that convert into common shares.
What are deferred stock units (DSUs) in the context of Ingevity (NGVT) director compensation?
The filing explains that the reported amount represents vested deferred stock units (DSUs) granted because the director elected to receive DSUs instead of cash quarterly director fees under Ingevity’s non-employee director compensation plans.
What is the relationship of the reporting person to Ingevity Corp (NGVT)?
The reporting person, Francis David Segal, is identified as a director of Ingevity Corp in the filing.